Life Sciences Tools and Services
Company Overview of Metamark Genetics, Inc.
Metamark Genetics, Inc., a biotechnology company, develops function-based, prognostic and diagnostic tests focusing on enhancing cancer care. The company’s genomic and proteomic discovery platforms develop solutions for various disease areas, such as prostate, bladder, colon, and breast cancers. It also provides specialty urological pathology testing services comprising prostate biopsy; triple stain; assessment of loss of PTEN function; ProMark, a prostate cancer prognostic test that differentiates indolent from aggressive disease; urine cytology; FISH molecular cytology; and other uropathology services to urologists, pathologists, and their patients in the United States. In addition, the co...
245 First Street
Cambridge, MA 02142
Founded in 2007
Key Executives for Metamark Genetics, Inc.
Chief Executive Officer, President and Director
Co-Founder, Director and Scientific & Clinical Advisor
Co-Founder, Consultant and Scientific & Clinical Advisor
Chief Financial Officer and Senior Vice President
Compensation as of Fiscal Year 2014.
Metamark Genetics, Inc. Key Developments
Metamark Appoints Anjen Chenn to Senior Vice President of Clinical Operations
Dec 1 14
Metamark announced that Anjen Chenn has been named the company's new Senior Vice President of clinical operations. Dr. Chenn will oversee operational execution and pathology services, across Metamark's three laboratories in Cambridge, Massachusetts; Collegeville, Pennsylvania; and Augusta, Georgia. Dr. Chenn most recently served as the associate professor of pathology at the University of Illinois.
Metamark Announces Nationwide Availability of ProMark(TM) Prostate Cancer Test
Oct 9 14
Metamark announced the nationwide availability of ProMark(TM), the first-of-it's-kind protein-based biopsy test designed to improve the accuracy of prognosis for men diagnosed with prostate cancer. For the 205,000 men annually with indeterminate Gleason scores (3+3 and 3+4), ProMark can help identify aggressiveness of the disease. ProMark has been validated in multiple clinical studies totaling more than 1,250 cases, all of which demonstrated the ability to differentiate between aggressive and non-aggressive forms of prostate cancer at early stages of disease. Results of a blinded clinical validation study were presented at the 2014 American Society of Clinical Oncology annual meeting, which showed ProMark predicted which patients had low-risk disease with a high sensitivity, thereby helping to identify patients who may be appropriate candidates for active surveillance or in need of aggressive therapy.
Metamark Announces the Expansion of its Prostate Cancer Test Services to Now Include the PROGENSA(R) PCA3 Assay
Sep 29 14
Metamark announced the expansion of its prostate cancer test services to now include the PROGENSA(R) PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay. These tests join Metamark's current portfolio, including ProMark(TM), the only protein-based prognostic test for prostate cancer that will soon be available nationwide. These new options provide patients and their doctors the additional information that can inform a more accurate assessment of their disease, which can lead to better guidance on treatment options. The PROGENSA(R) PCA3 assay is the first urine-based molecular test to provide an extra layer of assurance for at-risk men who have already received one or more negative biopsies. The test measures the Prostate Cancer Gene 3, or PCA3, which is expressed 60 to 100 times more often in prostate cancer than in normal cells. A low PCA3 score indicates a decreased likelihood of a positive repeat biopsy result. This ability to improve the diagnosis of prostate cancer can potentially reduce the need for many repeat biopsies. The PROGENSA(R) PCA3 assay is provided to Metamark by Hologic. ERG gene fusion has been noted as an indicator of cancer cell growth, driving the deletion of PTEN, a tumor suppressor gene. In several studies, PTEN loss combined with ERG fusion has been associated with aggressive prostate cancer cells. These indicators are helpful for predicting the likely course of prostate cancer progression. ERG in conjunction with PTEN can be informative in patients who have pre-cancerous conditions or low grade prostate cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|